Em meio à busca humana por respostas diante de uma pandemia que desafiou certezas, um estudo malaio com quinhentos pacientes veio reafirmar o que a ciência vinha sinalizando: a ivermectina não protege contra a progressão da COVID-19. Mais do que confirmar sua ineficácia, a pesquisa revelou que o medicamento pode causar danos reais — especialmente para os mais vulneráveis. É um lembrete de que a esperança, quando desvinculada da evidência, pode se tornar um risco em si mesma.
Olhar Digital
· Feb 21, 2022
· health
· 1 min read
High
Sourcing: Verified
Malaysian study confirms ivermectin ineffective for COVID-19, linked to severe adverse effects
Study participants experienced severe adverse events including acute diarrhea with fluid loss and myocardial infarction cases; 13 deaths occurred though not attributed to ivermectin.
◉
Health & Medicine
2821 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Brazil Gets New Blood Test for Early Alzheimer's Detection
Olhar Digital · 90% match
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% match
Related Coverage
REDE BRASIL DE TELEVISÃO · Aug 25
Endocrinologista explica por que emagrecer após os 40 exige abordagem integral
Endocrinologista explica que perda de peso após os 40 anos exige análise integrada de hormônios, sono e composição corpo…
Folha de S.Paulo · Aug 25 Zema critica vacinação obrigatória e nega golpe em entrevista ao Jornal NacionalCandidato presidencial Romeu Zema declarou-se contrário à vacinação obrigatória e prometeu anistia aos condenados pelos …
Super Rádio Tupi · Aug 25 Nova espécie de cão-urso do Mioceno revela predador pré-histórico desconhecidoPesquisadores identificaram uma nova espécie de cão-urso (anficionídeo) em fósseis de 16 milhões de anos, ampliando o co…
REDE BRASIL DE TELEVISÃO · Aug 25 Diagnóstico precoce de Alzheimer amplia possibilidades de tratamento, alerta FebrazCampanha Setembro Lilás 2026 alerta sobre importância do diagnóstico inicial de Alzheimer, com 84,3% de subdiagnóstico n…
Geopolitical Impact
🌎
Malaysian COVID-19 study confirms ivermectin ineffectiveness and safety concerns; primarily a public health finding with limited geopolitical significance.
Escalation Risk
low
Confidence
HIGH
Bias & Framing
⚖
Article presents Malaysian study findings on ivermectin with straightforward reporting of ineffectiveness and adverse effects, with minimal apparent bias in presentation.
Bias Direction
center
Confidence
MED
Evidence-based reporting: The article frames ivermectin through clinical trial results, emphasizing both ineffectiveness and safety concerns. Uses direct researcher quotes and specific data points (500 patients, 33 adverse events) to support conclusions.
inútil (useless)
quadro de diarreia grave (severe diarrhea condition)
levanta preocupações (raises concerns)
Statements from ivermectin proponents or alternative medicine advocates
Discussion of ivermectin's approved uses in other conditions
Context on why some populations pursued ivermectin despite limited evidence
Perspective from manufacturers or researchers who previously studied ivermectin for COVID-19
Economic Lens
📈
Malaysian study of 500 COVID-19 patients confirms ivermectin ineffective for disease prevention with significant adverse effects, particularly severe diarrhea, raising public health concerns about unsupervised off-label use.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical/Drug Manufacturing
Healthcare Services
Medical Research
Public Health Administration
Retail Pharmacy
Consumers who purchased ivermectin for COVID-19 treatment face wasted expenditure on an ineffective treatment with documented health risks. This undermines consumer confidence in self-medication and off-label drug use, potentially increasing demand for proven treatments and medical consultations.
Regulatory bodies should strengthen enforcement against off-label ivermectin promotion for COVID-19, implement stricter controls on unsupervised pharmaceutical distribution, and increase public education campaigns. Healthcare systems may need to address treatment costs for adverse effects and establish clearer guidelines for approved COVID-19 therapeutics.